Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency

Replacement intravenous immunoglobulin G (IVIG) is approved by the US Food and Drug Administration (FDA) for primary and secondary immune deficiency and is also used as an immunomodulatory agent for autoimmune and inflammatory disorders.1 Although IVIG is well tolerated, renal dysfunction occurs infrequently, most often in older patients with preexisting renal disease receiving a sucrose-containing IVIG product administered at a high dose as an immunomodulatory agent for hematologic or neurologic disease.

http://ift.tt/2haJxFT